Angioimmunoblastic T-cell lymphoma diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
According to the Lugano classification, there are four stages of angioimmunoblastic T-cell lymphoma based on the number of nodes and extranodal involvement. | According to the Lugano classification, there are four stages of angioimmunoblastic T-cell lymphoma based on the number of [[Lymph node|nodes]] and extranodal involvement. | ||
==Diagnostic Study of Choice== | ==Diagnostic Study of Choice== | ||
===Staging=== | ===Staging=== | ||
Staging for angioimmunoblastic T-cell lymphoma is provided in the following table:<ref>{{Cite journal| doi = 10.1200/JCO.2013.54.8800| issn = 1527-7755| volume = 32| issue = 27| pages = 3059–3068| last1 = Cheson| first1 = Bruce D.| last2 = Fisher| first2 = Richard I.| last3 = Barrington| first3 = Sally F.| last4 = Cavalli| first4 = Franco| last5 = Schwartz| first5 = Lawrence H.| last6 = Zucca| first6 = Emanuele| last7 = Lister| first7 = T. Andrew| last8 = Alliance, Australasian Leukaemia and Lymphoma Group| last9 = Eastern Cooperative Oncology Group| last10 = European Mantle Cell Lymphoma Consortium| last11 = Italian Lymphoma Foundation| last12 = European Organisation for Research| last13 = Treatment of Cancer/Dutch Hemato-Oncology Group| last14 = Grupo Español de Médula Ósea| last15 = German High-Grade Lymphoma Study Group| last16 = German Hodgkin's Study Group| last17 = Japanese Lymphorra Study Group| last18 = Lymphoma Study Association| last19 = NCIC Clinical Trials Group| last20 = Nordic Lymphoma Study Group| last21 = Southwest Oncology Group| last22 = United Kingdom National Cancer Research Institute| title = Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification| journal = Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology| date = 2014-09-20| pmid = 25113753}}</ref> | [[Cancer staging|Staging]] for angioimmunoblastic T-cell lymphoma is provided in the following table:<ref>{{Cite journal| doi = 10.1200/JCO.2013.54.8800| issn = 1527-7755| volume = 32| issue = 27| pages = 3059–3068| last1 = Cheson| first1 = Bruce D.| last2 = Fisher| first2 = Richard I.| last3 = Barrington| first3 = Sally F.| last4 = Cavalli| first4 = Franco| last5 = Schwartz| first5 = Lawrence H.| last6 = Zucca| first6 = Emanuele| last7 = Lister| first7 = T. Andrew| last8 = Alliance, Australasian Leukaemia and Lymphoma Group| last9 = Eastern Cooperative Oncology Group| last10 = European Mantle Cell Lymphoma Consortium| last11 = Italian Lymphoma Foundation| last12 = European Organisation for Research| last13 = Treatment of Cancer/Dutch Hemato-Oncology Group| last14 = Grupo Español de Médula Ósea| last15 = German High-Grade Lymphoma Study Group| last16 = German Hodgkin's Study Group| last17 = Japanese Lymphorra Study Group| last18 = Lymphoma Study Association| last19 = NCIC Clinical Trials Group| last20 = Nordic Lymphoma Study Group| last21 = Southwest Oncology Group| last22 = United Kingdom National Cancer Research Institute| title = Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification| journal = Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology| date = 2014-09-20| pmid = 25113753}}</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center | {| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | ||
|+ '''Revised staging system for primary nodal lymphomas (Lugano classification)''' | |+ '''Revised staging system for primary nodal lymphomas (Lugano classification)''' | ||
! style="background: #4479BA; color:#FFF;" | Stage | ! style="background: #4479BA; color:#FFF;" | Stage | ||
| Line 15: | Line 15: | ||
! style="background: #4479BA; color:#FFF;" | Extranodal (E) status | ! style="background: #4479BA; color:#FFF;" | Extranodal (E) status | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" | | colspan="3" style="padding: 5px 5px; background: #DCDCDC;" | '''Limited''' | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | I | | style="padding: 5px 5px; background: #F5F5F5;" | '''I''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | One node or a group of adjacent nodes | | style="padding: 5px 5px; background: #F5F5F5;" | One node or a group of adjacent [[Lymph node|nodes]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Single extranodal lesions without nodal involvement | | style="padding: 5px 5px; background: #F5F5F5;" | Single extranodal [[Lesion|lesions]] without [[Lymph node|nodal]] involvement | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | II | | style="padding: 5px 5px; background: #F5F5F5;" | '''II''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Two or more nodal groups on the same side of the diaphragm | | style="padding: 5px 5px; background: #F5F5F5;" | Two or more [[Lymph node|nodal]] groups on the same side of the [[Thoracic diaphragm|diaphragm]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Stage I or II by nodal extent with limited contiguous extranodal involvement | | style="padding: 5px 5px; background: #F5F5F5;" | [[Cancer staging|Stage]] I or II by [[Lymph node|nodal]] extent with limited contiguous extranodal involvement | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | II Bulky | | style="padding: 5px 5px; background: #F5F5F5;" | '''II Bulky''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | II as above with "bulky" disease | | style="padding: 5px 5px; background: #F5F5F5;" | II as above with "bulky" disease | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Not applicable | | style="padding: 5px 5px; background: #F5F5F5;" | Not applicable | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" | | colspan="3" style="padding: 5px 5px; background: #DCDCDC;" | '''Advanced''' | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | III | | style="padding: 5px 5px; background: #F5F5F5;" | '''III''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Nodes on both sides of the diaphragm; nodes above the diaphragm with spleen involvement | | style="padding: 5px 5px; background: #F5F5F5;" | [[Lymph node|Nodes]] on both sides of the [[Thoracic diaphragm|diaphragm]]; [[Lymph node|nodes]] above the [[Thoracic diaphragm|diaphragm]] with [[spleen]] involvement | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Not applicable | | style="padding: 5px 5px; background: #F5F5F5;" | Not applicable | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | IV | | style="padding: 5px 5px; background: #F5F5F5;" | '''IV''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Additional noncontiguous extralymphatic involvement | | style="padding: 5px 5px; background: #F5F5F5;" | Additional noncontiguous [[Lymphatic system|extralymphatic]] involvement | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Not applicable | | style="padding: 5px 5px; background: #F5F5F5;" | Not applicable | ||
|} | |} | ||
Revision as of 17:25, 4 April 2019
|
Angioimmunoblastic T-cell lymphoma Microchapters |
|
Differentiating Angioimmunoblastic T-cell lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Angioimmunoblastic T-cell lymphoma diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Angioimmunoblastic T-cell lymphoma diagnostic study of choice |
|
FDA on Angioimmunoblastic T-cell lymphoma diagnostic study of choice |
|
CDC on Angioimmunoblastic T-cell lymphoma diagnostic study of choice |
|
Angioimmunoblastic T-cell lymphoma diagnostic study of choice in the news |
|
Blogs on Angioimmunoblastic T-cell lymphoma diagnostic study of choice |
|
Directions to Hospitals Treating Angioimmunoblastic T-cell lymphoma |
|
Risk calculators and risk factors for Angioimmunoblastic T-cell lymphoma diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
According to the Lugano classification, there are four stages of angioimmunoblastic T-cell lymphoma based on the number of nodes and extranodal involvement.
Diagnostic Study of Choice
Staging
Staging for angioimmunoblastic T-cell lymphoma is provided in the following table:[1]
| Stage | Involvement | Extranodal (E) status |
|---|---|---|
| Limited | ||
| I | One node or a group of adjacent nodes | Single extranodal lesions without nodal involvement |
| II | Two or more nodal groups on the same side of the diaphragm | Stage I or II by nodal extent with limited contiguous extranodal involvement |
| II Bulky | II as above with "bulky" disease | Not applicable |
| Advanced | ||
| III | Nodes on both sides of the diaphragm; nodes above the diaphragm with spleen involvement | Not applicable |
| IV | Additional noncontiguous extralymphatic involvement | Not applicable |
References
- ↑ Cheson, Bruce D.; Fisher, Richard I.; Barrington, Sally F.; Cavalli, Franco; Schwartz, Lawrence H.; Zucca, Emanuele; Lister, T. Andrew; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute (2014-09-20). "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 32 (27): 3059–3068. doi:10.1200/JCO.2013.54.8800. ISSN 1527-7755. PMID 25113753.